Genocea Presents Follow-up Data from GEN-009 Neoantigen Vaccine Phase 1/2a Trial at ESMO Virtual Congress 2020 - Seite 2
“Our findings, which show that RECIST responses were maintained for at least three months in three of the five patients evaluated, underscore the potential of GEN-009 to boost CPI regimens in hard to treat patients,” said Thomas Davis, M.D., Chief Medical Officer of Genocea. “We believe that the path forward to designing better immunotherapies is powered by ATLAS. These results build further confidence that we are indeed targeting relevant tumor antigens for inclusion in our GEN-009 vaccine.”
The company expects to share additional immunogenicity and clinical data from the remaining 10 Part B patients later this year.
About Genocea Biosciences, Inc.
Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS platform comprehensively profiles each patient’s T cell responses
to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an
immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our neoantigen-specific
cell therapy using T cells derived from peripheral blood for which we expect to conduct a Phase 1/2a clinical trial. To learn more, please visit www.genocea.com.
Forward-Looking Statements
This press release includes forward-looking statements, including statements relating to GEN-009 and GEN-011, within the meaning of the Private Securities Litigation Reform Act. Such
forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that
these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading
"Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of
this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.
Lesen Sie auch
Investor Contact:
Dan Ferry
617-430-7576
daniel@lifesciadvisors.com